{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T16:23:58Z","timestamp":1787847838013,"version":"build-2784847793"},"reference-count":18,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,4]]},"abstract":"<jats:sec>\n                    <jats:title>BACKGROUND:<\/jats:title>\n                    <jats:p>The first cases of the coronavirus disease 2019 (COVID-19) were reported in Wuhan, China. No antiviral treatment options are currently available with proven clinical efficacy. However, preliminary findings from phase III trials suggest that remdesivir is an effective and safe treatment option for COVID-19 patients with both moderate and severe disease.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>OBJECTIVE:<\/jats:title>\n                    <jats:p>The aim of the present meta-analysis was to investigate whether remdesivir was effective for treating COVID-19 including reduced in-hospital adverse events, oxygen support, and mortality rates.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>METHODS:<\/jats:title>\n                    <jats:p>According to the PRISMA reporting guidelines, a review was conducted from January 1, 2020, until August 25, 2020, with MeSH terms including COVID-19, COVID, coronavirus, SARS-CoV-2, remdesivir, adenosine nucleoside triphosphate analog, and Veklury using MEDLINE, Scopus, and CINAHL Plus. A modified Delphi process was utilized to include the studies and ensure that the objectives were addressed. Using dichotomous data for select values, the unadjusted odds ratios (ORs) were calculated applying Mantel\u2013Haenszel random-effects method in Review Manager 5.4.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESULTS:<\/jats:title>\n                    <jats:p>\n                      Randomized controlled trials pooled in 3013 participants with 46.3% (\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      = 1395) in the remdesivir group and 53.7% (\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      = 1618) in the placebo group. The placebo group had a higher risk of mortality as compared to the intervention group with significant OR (0.61) (95% confidence interval of 0.45\u20130.82;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.001). There was minimal heterogeneity among the studies (\n                      <jats:italic toggle=\"yes\">I<\/jats:italic>\n                      <jats:sup>2<\/jats:sup>\n                      = 0%).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSIONS:<\/jats:title>\n                    <jats:p>Our findings suggest that remdesivir extends clinical benefits by reducing mortality, adverse events, and oxygen support in moderate to severely ill COVID-19 patients. Concerted efforts and further randomized placebo-controlled trials are warranted to examine the potency of antiviral drugs and immunopathological host responses contributing to the severity of COVID-19.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/2452-2473.309139","type":"journal-article","created":{"date-parts":[[2021,2,11]],"date-time":"2021-02-11T19:17:13Z","timestamp":1613071033000},"page":"43-50","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":6,"title":["Randomized controlled trials of remdesivir in hospitalized coronavirus disease 2019 patients"],"prefix":"10.4103","volume":"21","author":[{"given":"Azza","family":"Sarfraz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zouina","family":"Sarfraz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcos","family":"Sanchez-Gonzalez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jack","family":"Michel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Michel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Odalys","family":"Frontela","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge","family":"Posada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose","family":"Cardona","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eugenio","family":"Angueira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R3-1-20240909","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1021\/acscentsci.0c00489","article-title":"Remdesivir: A review of its discovery and development leading to emergency use authorization for treatment of COVID-19","volume":"6","author":"Eastman","year":"2020","journal-title":"ACS Cent Sci"},{"key":"R5-1-20240909","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1016\/S0140-6736(20)31022-9","article-title":"Remdesivir in adults with severe COVID-19: A randomised, double-blind, placebo-controlled, multicentre trial","volume":"395","author":"Wang","year":"2020","journal-title":"Lancet"},{"key":"R6-1-20240909","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1126\/scitranslmed.aal3653","article-title":"Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses","volume":"9","author":"Sheahan","year":"2017","journal-title":"Sci Transl Med"},{"key":"R8-1-20240909","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1038\/s41467-019-13940-6","article-title":"Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV","volume":"11","author":"Sheahan","year":"2020","journal-title":"Nat Commun"},{"key":"R9-1-20240909","first-page":"1","article-title":"Role of GS-5734 (remdesivir) in inhibiting SARS-CoV and MERS-CoV: The expected role of GS-5734 (remdesivir) in COVID-19 (2019-nCoV)-VYTR hypothesis","volume":"1","author":"Yethindra","year":"2020","journal-title":"Int J Res Pharm Sci"},{"key":"R10-1-20240909","first-page":"297","article-title":"Consideration on the strategies during epidemic stage changing from emergency response to continuous prevention and control","volume":"41","author":"Hua","year":"2020","journal-title":"Chinese J Endem"},{"key":"R11-1-20240909","doi-asserted-by":"crossref","first-page":"2327","DOI":"10.1056\/NEJMoa2007016","article-title":"Compassionate use of remdesivir for patients with severe Covid-19","volume":"382","author":"Grein","year":"2020","journal-title":"N Engl J Med"},{"key":"R13-1-20240909","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1056\/NEJMoa2001191","article-title":"First case of 2019 novel coronavirus in the United States","volume":"382","author":"Holshue","year":"2020","journal-title":"N Engl J Med"},{"key":"R15-1-20240909","first-page":"ciaa1041","article-title":"Remdesivir for severe COVID-19 versus a cohort receiving standard of Care","volume":"24","author":"Olender","year":"2020","journal-title":"Clin Infect Dis"},{"key":"R16-1-20240909","first-page":"NEJMoa2007764","article-title":"Remdesivir for the treatment of COVID-19-Preliminary report","volume":"8","author":"Beigel","year":"2020","journal-title":"N Engl J Med"},{"key":"R18-1-20240909","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1186\/s13063-020-04352-9","article-title":"Evaluation of the efficacy and safety of intravenous remdesivir in adult patients with severe COVID-19: study protocol for a phase 3 randomized, double-blind, placebo-controlled, multicentre trial","volume":"21","author":"Wang","year":"2020","journal-title":"Trials"},{"key":"R19-1-20240909","doi-asserted-by":"crossref","first-page":"m1610","DOI":"10.1136\/bmj.m1610","article-title":"Remdesivir in COVID-19","volume":"369","author":"Ferner","year":"2020","journal-title":"BMJ"},{"key":"R20-1-20240909","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1007\/s40264-020-00952-1","article-title":"Remdesivir in treatment of COVID-19: A systematic benefit-risk assessment","volume":"43","author":"Davies","year":"2020","journal-title":"Drug Saf"},{"key":"R21-1-20240909","doi-asserted-by":"crossref","first-page":"100455","DOI":"10.1016\/j.eclinm.2020.100455","article-title":"The association of race and COVID-19 mortality","volume":"25","author":"Golestaneh","year":"2020","journal-title":"EClinicalMedicine"},{"key":"R22-1-20240909","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1001\/jama.283.8.1016","article-title":"Efficacy and safety of the oral neuraminidase inhibitor oseltamivir in treating acute influenza: A randomized controlled trial","volume":"283","author":"Treanor","year":"2000","journal-title":"JAMA"},{"key":"R23-1-20240909","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1001\/jama.1984.03350090023017","article-title":"Double-blind placebo-controlled trial of oral acyclovir in first-episode genital herpes simplex virus infection","volume":"252","author":"Mertz","year":"1984","journal-title":"JAMA"},{"key":"R24-1-20240909","doi-asserted-by":"crossref","first-page":"e59","DOI":"10.1056\/NEJMp2021971","article-title":"Racial disproportionality in COVID clinical trials","volume":"383","author":"Chastain","year":"2020","journal-title":"N Engl J Med"},{"key":"R25-1-20240909","doi-asserted-by":"crossref","first-page":"m2924","DOI":"10.1136\/bmj.m2924","article-title":"Remdesivir for severe COVID-19: A clinical practice guideline","volume":"370","author":"Rochwerg","year":"2020","journal-title":"BMJ"}],"container-title":["Turkish Journal of Emergency Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/2452-2473.309139","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T15:40:23Z","timestamp":1787845223000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/2452-2473.309139"}},"subtitle":["A meta-analysis"],"short-title":[],"issued":{"date-parts":[[2021,4]]},"references-count":18,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.4103\/2452-2473.309139","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2020.08.21.20179200","asserted-by":"object"}]},"ISSN":["2452-2473"],"issn-type":[{"value":"2452-2473","type":"print"}],"subject":[],"published":{"date-parts":[[2021,4]]}}}